A research blog from the NCI Division of Cancer Prevention Subscribe Collaboration Spurs Rapid Growth and Progress in Cardio-Oncology Research August 8, 2023 | By DCP Staff Cardio-oncology research looks at cancer treatment-related cardiotoxicity, or damage to the heart and cardiovascular system (including heart valves and vessels) that can occur during or after cancer treatment. Over the last decade, efforts from the National Cancer Institute (NCI) in this area, as well as the field in general, have expanded significantly. U.S. Study Shows HPV Antibodies Remain High Up to 2 Years After a Single Dose of HPV Vaccine July 18, 2023 | By Linda Wang After receiving an initial single dose of the HPV vaccine Gardasil 9, children aged 9 to 11 had high levels of two key antibodies that protect against HPV infections and cancer for up to 2 years before receiving their delayed booster dose, according to results from a clinical trial supported by NCI. Important Symptom Management Findings Presented at 2023 ASCO Meeting June 13, 2023 | By DCP Staff Results from two NCI-supported studies relating to symptom management were among the significant findings presented at the June 2023 ASCO meeting. The findings, which both incorporated data from patient-reported outcomes (PROs), have the potential to help reduce toxic side effects and improve quality of life for people with cancer. Research Highlights: Investigating Associations of Obesity with Colorectal and GI Cancers June 5, 2023 | By DCP Staff An estimated 153,020 men and women in the U.S. will be diagnosed with colorectal cancer in 2023, and 52,550 are expected to die of this disease. In two recent studies, researchers addressed the impact of overweight, obesity, and body mass index (BMI) on colorectal and non-colorectal gastrointestinal (GI) cancers at different stages of adult life, as well as the association of BMI and different molecular subtypes in colorectal cancers. Eliminating Underlying Liver Disease Remains Key Strategy for Liver Cancer Prevention May 4, 2023 | By Susan Jenks Despite intense research, liver cancer prevention remains a challenge. Current efforts are directed at underlying conditions that can significantly raise an individual’s risk, including hepatitis C infection, for which researchers are working to find a vaccine. NCI Supports New Research into Prevention of Early-Onset Colorectal Cancer March 22, 2023 | By Susan Jenks Early-onset colorectal cancer is considered relatively rare, but both incidence and mortality rates are increasing in people under age 50. NCI recently issued a special research request for grant applications–in areas such as risk factors, biomarkers, screening methods, and preventive interventions. Trials Test Vaccines for Prevention or Delay of Cancers Associated with Lynch Syndrome February 8, 2023 | By Susan Jenks Researchers have recruited the first vaccine candidates to one of two new prevention trials that seek to immunize high-risk individuals against cancers associated with Lynch syndrome, the most common cause of hereditary colorectal cancer. Individuals who inherit the condition have an estimated lifetime risk as high as 80% for developing one of these malignancies, as well as an above-average risk for cancers arising in other organs, often at an early age, and regardless of race or gender. NCI Funding Approved to Expand Research on Immunoprevention, Natural Products January 10, 2023 | By DCP Staff The National Cancer Institute’s (NCI’s) Board of Scientific Advisors (BSA) recently approved two new concept proposals aimed at expanding potential prevention interventions. One will strengthen research in the nascent field of immunoprevention, and the other will accelerate the development of novel natural products for intercepting cancer at the earliest stages of disease. Research Highlights: Learning More about Breast Cancer Prevention in Primary Care Settings November 28, 2022 | By DCP Staff This month’s Research Highlights focuses on provider and patient beliefs about mammogram screening frequency, and separately, provider barriers to engaging in shared decision-making with high-risk patients about the use of chemoprevention to reduce breast cancer risk. Both studies discuss the value of and barriers to using decision-support tools designed to help in the delivery of optimal preventive care. Launching 'CASCADE': A Clinical Trials Network to Optimize Cervical Cancer Screening and Precancer Treatment for the Vulnerable Population of Women Living With HIV November 14, 2022 | By Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H. Cervical cancer can be prevented by human papillomavirus (HPV) vaccination and by screening for and treating precancerous lesions. Yet, millions of women globally remain at high-risk for developing cervical cancer. This is especially true for women living in resource-limited settings in low- and middle-income countries (LMICs) where access to prevention services is significantly limited. But this is also true for women facing health disparities within the United States, where half of all cervical cancers occur in women who have never been screened or rarely screened. Pagination « First First page ‹ Previous Previous page 1 2 3 4 … Next › Next page Last » Last page
